OmniCorder Technologies' BioScanIR System Shown Effective in Mapping Perforated Vessels for Pre-Operative Surgical Planning.

EAST SETAUKET, N.Y. -- OmniCorder Technologies, Inc. (OTCBB:OMCT) today announced that the Company's BioScanIR(R) System was the subject of a recent study published in the June issue of Physics in Medicine and Biology. A team led by Dr. Tiziano Binzoni, and Pr. Daniel Rufenacht, Departments of Radiology and Physiology, Faculty of Medicine, University of Geneva, Switzerland, examined the use of the company's Quantum Well Infrared Photodetector (QWIP) technology, used in the Company's BioScanIR(R) System, to map human skeletal muscle perforator vessels.

The study first describes limitations in other existing modalities such as near infrared spectroscopy (NIRS) and laser Doppler flowmetry (LDF), two commonly used techniques for non-invasive study of muscle metabolism and blood perfusion, and how QWIP technology can be implemented to overcome some of their limitations such as spatial variability, which makes the data interpretation and comparison difficult.

The study reported that the accurate comparison of the metabolic activity of two different muscle regions is not possible without reliable maps of vascular 'singularities' such as the perforator vessels and that OmniCorder's BioScanIR(R) imaging system can more accurately and more quickly obtain this important information.

The study's authors concluded that "... (the BioScanIR(R) system's) QWIP-based passive infrared imaging appears to be an efficient, effective, non-invasive method of mapping perforator vessels and may be an important surgical planning tool for reconstructive surgery."

Mark A. Fauci, OmniCorder Technologies, Inc.'s CEO and President, commented, "We are encouraged by the positive findings of the Geneva study as it builds on our clinical and scientific body of knowledge that supports the clinical utility of our BioScanIR(R) System in surgical applications." Mr. Fauci added, "The positive data from this study and feedback from the research team led us to further develop application specific tools that enhance the BioScanIR(R) System's use for pre-operative surgical planning in reconstructive surgery. A study testing these new capabilities is nearing completion and we look forward to its publication in the near future."

The BioScanIR(R) System:

The Company's BioScanIR(R) System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR(R) System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.

About OmniCorder Technologies, Inc.:

OmniCorder Technologies Inc., headquartered in East Setauket, New York, is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.

OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.

The Company announced a $7.8 million funding which coincided with the reverse acquisition of a publicly traded company in December 2003.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.